Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Recent Highlights: Qutenza® (capsaicin) 8% patch U.S. launch progress includes: Sales of Qutenza to end user customers reached $1.0 million in 3Q11, an increase of 22% over...
-
SAN MATEO, Calif., Oct. 31, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
-
SAN MATEO, Calif., Oct. 27, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
-
SAN MATEO, Calif., Sept. 27, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced...
-
Received U.S. FDA Orphan Drug and Fast Track Designations for the Potential Use of Qutenza to Treat Painful HIV-PN Qutenza Currently Approved by U.S. FDA for the Management of Neuropathic...
-
SAN MATEO, Calif., Sept. 1, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced...